Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Pegunigalsidase alfa

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
    NICE recommends Chiesi’s Elfabrio for adults with Fabry disease

    05 Sep 2023

    // PM LIVE

    https://www.pmlive.com/pharma_news/nice_recommends_chiesis_elfabrio_for_adults_with_fabry_disease_1497865

    PM LIVE
    05 Sep 2023
    Share Share
    Chiesi Farmaceutici's Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe
    Chiesi Farmaceutici's Elfabrio (Pegunigalsidase alfa) Receives Approval in the Europe

    25 May 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/elfabrio-epar-medicine-overview_en.pdf

    EMA
    25 May 2023
    Share Share
    Chiesi's Biologic Elfabrio (Pegunigalsidase alfa) Receives Approval in the U.S.
    Chiesi's Biologic Elfabrio (Pegunigalsidase alfa) Receives Approval in the U.S.

    09 May 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761161

    FDA
    09 May 2023
    Share Share
    Protalix & Chiesi gain positive opinion for pegunigalsidase alfa
    Protalix & Chiesi gain positive opinion for pegunigalsidase alfa

    06 Mar 2023

    // John Pinching PHARMATIMES

    https://www.pharmatimes.com/news/protalix_and_chiesi_gain_positive_opinion_for_pegunigalsidase_alfa_1488829

    John Pinching PHARMATIMES
    06 Mar 2023
    Share Share
    CHMP recommends first pegylated enzyme for Fabry disease
    CHMP recommends first pegylated enzyme for Fabry disease

    27 Feb 2023

    // EUROPEAN PHARMACEUTICAL REVIEW

    https://www.europeanpharmaceuticalreview.com/news/179980/chmp-recommends-first-pegylated-enzyme-for-fabry-disease/

    EUROPEAN PHARMACEUTICAL REVIEW
    27 Feb 2023
    Share Share
    Chiesi & Protalix Receive Positive CHMP Opinion for Pegunigalsidase Alfa
    Chiesi & Protalix Receive Positive CHMP Opinion for Pegunigalsidase Alfa

    25 Feb 2023

    // BIOSPACE

    https://www.biospace.com/article/releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-receive-positive-chmp-opinion-for-pegunigalsidase-alfa-for-treatment-of-fabry-disease/

    BIOSPACE
    25 Feb 2023
    Share Share